HIM
TBPH icon

Hillhouse Investment Management’s Theravance Biopharma TBPH Stock Holding History

Hillhouse Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-122,856
Closed -$4.89M – 56
2017
Q2 		$4.89M Sell
122,856
-181,400
-60% -$6.97M 0.08% 47
2017
Q1 		$11.2M Hold
304,256
– – 0.22% 28
2016
Q4 		$9.7M Buy
+304,256
New +$9.44M 0.22% 23

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Hillhouse Investment Management's TBPH Position: Q3 2017 in Review

Hillhouse Investment Management sold out of Theravance Biopharma (TBPH) in Q3 2017, closing a stake of 122,856 shares — an estimated $4.89M sold.

Hillhouse Investment Management first reported a position in TBPH in Q4 2016 and held it in 3 quarters. The position peaked at $11.2M in Q1 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q3 2017.

  • Hillhouse Investment Management reported no remaining Theravance Biopharma position as of Q3 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 122,856 Theravance Biopharma shares in Q3 2017, an estimated $4.89M.
  • Hillhouse Investment Management first reported a position in Theravance Biopharma in Q4 2016 and held it in 3 quarters.
  • Hillhouse Investment Management's Theravance Biopharma position peaked at $11.2M in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2017.

Based on Hillhouse Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.